Envafolimab plus chemo for stage IIb bone cancer before surgery
Part of Cancer clinical trials.
This trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy before surgery can help treat stage IIb osteosarcoma (a type of bone cancer) that hasn't spread. The goal is to see if this combination makes the tumor shrink more and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 70 years old.
- You have been diagnosed with stage IIb osteosarcoma that can be removed with surgery and has not spread to other parts of the body.
- You have not had any previous cancer treatment, including chemotherapy or radiation.
- You are in good overall health (ECOG score 0 or 1) and your vital organs (bone marrow, liver, kidneys) are working well.
- You do not have any other active cancers, serious infections, or autoimmune diseases.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests envalolimab (an immunotherapy) alone or with chemo (CAPEOX) before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.